Welcome to our dedicated page for AVALYN PHARMACEUTICALS news (Ticker: AVLN), a resource for investors and traders seeking the latest updates and insights on AVALYN PHARMACEUTICALS stock.
Avalyn Pharma Inc. reports news about its clinical-stage development of inhaled therapies for serious, rare respiratory diseases. Recurring company updates cover AP01 and AP02, pulmonary fibrosis research, clinical presentations, peer-reviewed publications, patient-centered treatment research, and respiratory-disease conference activity.
Company news also includes public-company developments such as the closing of its initial public offering, Nasdaq listing of AVLN common stock, capital-structure updates, governance changes, leadership appointments, clinical or regulatory disclosures, and operating and financial results tied to its rare lung disease pipeline.
Avalyn (Nasdaq: AVLN) will present two patient-centered research posters at the American Thoracic Society 2026 International Conference in Orlando, May 15-20, 2026.
Presentations cover a usability study of the eFlow® Nebulizer for AP01 (inhaled pirfenidone) and patient perspectives on supportive care in idiopathic pulmonary fibrosis. Posters P60 and P68 will be shown May 18, 11:30 a.m.-1:15 p.m.; abstracts appear in AJRCCM.
Two River and Vida Ventures acknowledged UCB's acquisition of Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront. Two River and Third Rock helped found Candid via the merger of TRC 2004 and Vignette Bio; Vida was an early investor. The announcement highlights Bellco Health's company-creation and investment track record, and notes Vida's 2025 M&A activity and two oversubscribed 2026 IPOs including Aktis Oncology (AKTS) and Avalyn Pharma (AVLN).
Avalyn (Nasdaq: AVLN) closed its initial public offering on May 1, 2026, selling an aggregate 19,166,667 shares of common stock, which includes the underwriters' full exercise of a 2,500,000-share overallotment option at $18.00 per share.
The aggregate gross proceeds were $345 million before underwriting discounts, commissions and offering expenses. Avalyn's common stock is listed on the Nasdaq Global Select Market under the ticker AVLN. Joint book-running managers were Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities.
Avalyn (Nasdaq: AVLN) priced an upsized initial public offering of 16,666,667 common shares at $18.00 per share, expected to raise approximately $300 million in gross proceeds before underwriting discounts, commissions and expenses. The underwriters have a 30-day option to purchase an additional 2,500,000 shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on April 30, 2026, with the offering expected to close on May 1, 2026, subject to customary conditions.
Avalyn (NYSE:AVLN) announced April 27, 2026 the appointments of Adam Golden as General Counsel and Head of Business Development and Frank Salisbury as Senior Vice President, Commercial.
Adam Golden brings over 30 years of legal and business development experience including senior roles at Freshfields, Hogan Lovells, and Kaye Scholer. Frank Salisbury brings 24+ years of commercial leadership and prior launches of therapies including ESBRIET and WINREVAIR. The hires target clinical advancement and commercial readiness ahead of future commercialization.
Avalyn (NASDAQ:AVLN) appointed Jon Congleton to its Board of Directors on April 6, 2026. Congleton brings nearly 40 years of biopharma experience and current CEO experience at Mineralys, with expertise in commercial strategy and organizational leadership.
His appointment is positioned to support Avalyn's Phase 2 programs, MIST for AP01 and AURA for AP02, and preparation for late‑stage development and commercialization.
Avalyn (NASDAQ:AVLN) announced a peer-reviewed publication (BMC Pulmonary Medicine, March 25, 2026) reporting that quantitative HRCT imaging changes with inhaled AP01 (pirfenidone) correlated with lung function and quality-of-life improvements in Phase 1b ATLAS patients.
Key results: >70% of AP01 100 mg BID patients with baseline and Week 24 imaging showed stabilization or improvement in fibrosis score; QOL gains appeared by Week 8 and persisted to Week 48. Avalyn plans HRCT in upcoming Phase 2 MIST and AURA trials; additional longitudinal data expected mid-2026.